STOCK TITAN

GRI Bio (GRI) 10-K Filings

GRI NASDAQ

Here are the 10-K annual reports from GRI Bio, Inc. (GRI) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow GRI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GRI filings page.

Rhea-AI Summary

GRI Bio, Inc. is a clinical‑stage biopharmaceutical company developing immune‑modulating therapies for inflammatory, fibrotic and autoimmune diseases, led by oral iNKT‑cell inhibitor GRI‑0621 for idiopathic pulmonary fibrosis (IPF) and dNKT‑cell agonist GRI‑0803 for lupus.

A 35‑patient Phase 2a IPF trial of GRI‑0621 met its primary safety endpoint and evaluated multiple biomarker and lung‑function measures, with no treatment‑related serious adverse events and generally manageable side effects. The company plans, subject to FDA input and additional funding, a Phase 2b study that could support conditional EU approval and potential U.S. registration.

GRI‑0803 showed disease‑modifying signals in preclinical lupus nephritis models, and the company aims to file an IND and start Phase 1a/1b studies in 2026. GRI emphasizes broad NKT‑cell biology expertise and a patent estate with expected expiries around 2032–2035.

The business remains highly dependent on raising substantial additional capital, and management has expressed substantial doubt about the company’s ability to continue as a going concern. The filing also highlights Nasdaq listing risk and previously identified material weaknesses in internal controls, only partially remediated.